Highlights from the 2024 ASCO Annual Meeting This year’s ASCO Annual Mee

Promising results also displayed the benefits of certain treatments for pa ents at high risk of recurrence and new op ons for pa ents with metasta c breast cancer. [...] Early Biomarkers predic ng response to immunotherapy more common in Black women Researchers FROM the Carolina Breast Cancer Study explored the poten al of biomarkers MHC-I and MHC-II to predict immune response to immunotherapy in breast cancer pa ents. [...] Read more Tailored chemotherapy can reduce toxicity and side effects for Black pa ents The ECOG-ACRIN Cancer Research Group conducted a study that aimed to iden fy gene c predictors for chemotherapy-induced peripheral neuropathy in Black pa ents with stage I to III breast cancer. [...] Read more Metastatic Abemaciclib improves outcomes in HR+, HER2- metasta c breast cancer a er ini al treatment Phase 3 of the postMONARCH trial studied the addi on of abemaciclib to fulvestrant for pa ents with HR+, HER2- mBC who had advanced on a CDK4/6 inhibitor and endocrine therapy. [...] Read more Inavolisib extends treatment me and delays progression in metasta c pa ents with PIK3CA muta on In updated results from phase 3 of the INAVO120 trial, adding inavolisib to palbociclib and fulvestrant significantly improved outcomes for pa ents with a PIK3CA muta on.